Radiation plus immunotherapy for locally advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of high-dose radiation (SBRT) and an immunotherapy drug called zimberelimab for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if the combination shrinks tumors or slows their growth better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have locally advanced pancreatic cancer that cannot be removed with surgery.
- The tumor hasn't grown into your stomach or intestines.
- You haven't had immunotherapy before.
- You must be able to undergo the tests and procedures required for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.